Last reviewed · How we verify
ACT-132577
At a glance
| Generic name | ACT-132577 |
|---|---|
| Also known as | Aprocitentan |
| Sponsor | Idorsia Pharmaceuticals Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety (PHASE3)
- A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects (PHASE1)
- A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood) (PHASE1)
- A Study to Evaluate ACT-132577 in Healthy Male Subjects (PHASE1)
- Clinical Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects (PHASE1)
- The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics (PHASE1)
- A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease. (PHASE3)
- Bioequivalence Study of Different Aprocitentan Tablet Formulations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACT-132577 CI brief — competitive landscape report
- ACT-132577 updates RSS · CI watch RSS
- Idorsia Pharmaceuticals Ltd. portfolio CI